 Myron Levin
Concepts (849)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 105 | 2024 | 316 | 18.380 |
Why?
| | Herpes Zoster Vaccine | 65 | 2024 | 159 | 16.840 |
Why?
| | Herpesvirus 3, Human | 86 | 2024 | 332 | 12.440 |
Why?
| | Chickenpox | 24 | 2023 | 83 | 5.130 |
Why?
| | Antibodies, Viral | 66 | 2024 | 625 | 5.080 |
Why?
| | Immunity, Cellular | 36 | 2024 | 268 | 4.680 |
Why?
| | Chickenpox Vaccine | 27 | 2023 | 73 | 3.890 |
Why?
| | Influenza Vaccines | 18 | 2024 | 539 | 2.930 |
Why?
| | Vaccines, Attenuated | 32 | 2024 | 132 | 2.740 |
Why?
| | HIV Infections | 38 | 2018 | 2836 | 2.540 |
Why?
| | Neuralgia, Postherpetic | 18 | 2019 | 40 | 2.450 |
Why?
| | Immunocompromised Host | 13 | 2019 | 202 | 2.420 |
Why?
| | Antiviral Agents | 28 | 2022 | 744 | 2.310 |
Why?
| | Adjuvants, Immunologic | 17 | 2023 | 226 | 2.170 |
Why?
| | Simplexvirus | 24 | 2016 | 80 | 2.130 |
Why?
| | Acyclovir | 27 | 2016 | 101 | 2.060 |
Why?
| | Herpes Simplex | 17 | 2016 | 95 | 1.920 |
Why?
| | Vaccination | 33 | 2023 | 1381 | 1.880 |
Why?
| | DNA, Viral | 24 | 2018 | 364 | 1.750 |
Why?
| | Trypanosoma cruzi | 13 | 2007 | 40 | 1.700 |
Why?
| | Papillomavirus Vaccines | 13 | 2018 | 238 | 1.630 |
Why?
| | Viral Envelope Proteins | 6 | 2021 | 84 | 1.490 |
Why?
| | Herpesvirus 1, Human | 10 | 2016 | 87 | 1.460 |
Why?
| | Pregnancy Complications, Infectious | 16 | 2020 | 394 | 1.430 |
Why?
| | Influenza, Human | 13 | 2024 | 622 | 1.400 |
Why?
| | Humans | 293 | 2024 | 137585 | 1.380 |
Why?
| | T-Lymphocytes | 20 | 2019 | 1996 | 1.370 |
Why?
| | Vaccines, Synthetic | 15 | 2023 | 126 | 1.360 |
Why?
| | Antiretroviral Therapy, Highly Active | 13 | 2017 | 271 | 1.350 |
Why?
| | Aged | 92 | 2024 | 23961 | 1.340 |
Why?
| | Aged, 80 and over | 47 | 2022 | 7635 | 1.310 |
Why?
| | Immunologic Memory | 12 | 2019 | 353 | 1.300 |
Why?
| | Immunization, Secondary | 13 | 2017 | 87 | 1.270 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2023 | 1091 | 1.240 |
Why?
| | Papillomavirus Infections | 9 | 2018 | 325 | 1.190 |
Why?
| | Antibodies, Protozoan | 5 | 2007 | 36 | 1.170 |
Why?
| | Middle Aged | 101 | 2024 | 33479 | 1.110 |
Why?
| | Ribosomal Proteins | 6 | 2006 | 93 | 1.070 |
Why?
| | Chagas Disease | 8 | 2007 | 44 | 1.040 |
Why?
| | Female | 155 | 2023 | 73304 | 1.030 |
Why?
| | Protozoan Proteins | 6 | 2006 | 82 | 1.020 |
Why?
| | Double-Blind Method | 32 | 2022 | 1993 | 1.010 |
Why?
| | Male | 138 | 2023 | 67762 | 0.980 |
Why?
| | T-Lymphocyte Subsets | 6 | 2019 | 417 | 0.960 |
Why?
| | Vaccines, Inactivated | 9 | 2023 | 68 | 0.910 |
Why?
| | Viral Vaccines | 12 | 2014 | 98 | 0.900 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2007 | 46 | 0.880 |
Why?
| | Incidence | 22 | 2023 | 2804 | 0.870 |
Why?
| | Herpesvirus 2, Human | 6 | 2014 | 29 | 0.860 |
Why?
| | Virus Latency | 4 | 2014 | 80 | 0.830 |
Why?
| | Interferon-gamma | 18 | 2022 | 789 | 0.830 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2019 | 74 | 0.820 |
Why?
| | Immune Sera | 4 | 2020 | 88 | 0.810 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2018 | 900 | 0.800 |
Why?
| | B-Lymphocytes | 9 | 2021 | 847 | 0.790 |
Why?
| | Pneumococcal Vaccines | 3 | 2021 | 142 | 0.790 |
Why?
| | Injections, Intramuscular | 5 | 2022 | 129 | 0.790 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 22 | 2021 | 852 | 0.770 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2017 | 148 | 0.750 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2019 | 36 | 0.740 |
Why?
| | Antibodies, Neutralizing | 12 | 2023 | 286 | 0.740 |
Why?
| | Age Factors | 17 | 2021 | 3295 | 0.740 |
Why?
| | Drug Resistance, Viral | 7 | 2009 | 116 | 0.730 |
Why?
| | Rotavirus Infections | 3 | 2017 | 43 | 0.720 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 6 | 2017 | 15 | 0.720 |
Why?
| | Influenza B virus | 6 | 2012 | 44 | 0.690 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 233 | 0.680 |
Why?
| | Vaccination Coverage | 2 | 2018 | 82 | 0.670 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 46 | 0.650 |
Why?
| | Adenovirus Infections, Human | 4 | 2015 | 15 | 0.640 |
Why?
| | Infectious Disease Transmission, Vertical | 7 | 2020 | 184 | 0.640 |
Why?
| | Down Syndrome | 2 | 2023 | 496 | 0.630 |
Why?
| | Adult | 76 | 2024 | 37929 | 0.630 |
Why?
| | Clinical Trials as Topic | 15 | 2019 | 1050 | 0.620 |
Why?
| | Polymerase Chain Reaction | 13 | 2019 | 1062 | 0.610 |
Why?
| | Th1 Cells | 3 | 2018 | 143 | 0.610 |
Why?
| | HIV | 4 | 2010 | 234 | 0.590 |
Why?
| | Insurance Claim Review | 1 | 2019 | 64 | 0.590 |
Why?
| | Child, Preschool | 42 | 2024 | 11074 | 0.590 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2015 | 127 | 0.590 |
Why?
| | Cytomegalovirus Infections | 4 | 2015 | 192 | 0.590 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2017 | 45 | 0.580 |
Why?
| | CD4 Lymphocyte Count | 14 | 2017 | 269 | 0.580 |
Why?
| | Alphapapillomavirus | 4 | 2016 | 39 | 0.580 |
Why?
| | Antibody Formation | 8 | 2023 | 298 | 0.570 |
Why?
| | Infant | 31 | 2023 | 9465 | 0.560 |
Why?
| | Immunoglobulin G | 11 | 2021 | 893 | 0.560 |
Why?
| | Dose-Response Relationship, Immunologic | 3 | 2016 | 82 | 0.560 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 0.550 |
Why?
| | Anti-HIV Agents | 6 | 2015 | 778 | 0.550 |
Why?
| | Child | 59 | 2024 | 21935 | 0.550 |
Why?
| | Pneumonia | 1 | 2023 | 639 | 0.540 |
Why?
| | Health Expenditures | 1 | 2019 | 189 | 0.540 |
Why?
| | Pain | 6 | 2022 | 756 | 0.530 |
Why?
| | Herpesviridae Infections | 4 | 2015 | 147 | 0.520 |
Why?
| | Cytosine | 3 | 2015 | 49 | 0.520 |
Why?
| | Adolescent | 53 | 2024 | 21513 | 0.520 |
Why?
| | Interleukin-2 | 7 | 2022 | 455 | 0.520 |
Why?
| | Infant, Premature | 5 | 2020 | 574 | 0.510 |
Why?
| | Organophosphonates | 2 | 2015 | 93 | 0.500 |
Why?
| | Antigens, Viral | 21 | 2017 | 178 | 0.500 |
Why?
| | Cytomegalovirus | 7 | 2006 | 157 | 0.490 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 157 | 0.490 |
Why?
| | Follow-Up Studies | 22 | 2019 | 5131 | 0.480 |
Why?
| | Guanine | 14 | 2006 | 79 | 0.480 |
Why?
| | Enzyme-Linked Immunospot Assay | 4 | 2018 | 36 | 0.480 |
Why?
| | Refrigeration | 2 | 2018 | 12 | 0.470 |
Why?
| | Health Care Costs | 1 | 2018 | 398 | 0.460 |
Why?
| | Viral Load | 12 | 2018 | 466 | 0.460 |
Why?
| | Polyomavirus Infections | 1 | 2015 | 31 | 0.460 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2016 | 257 | 0.450 |
Why?
| | Immunity, Humoral | 3 | 2021 | 116 | 0.450 |
Why?
| | Immunization | 5 | 2014 | 411 | 0.450 |
Why?
| | Oropharynx | 1 | 2014 | 46 | 0.440 |
Why?
| | Skin Diseases | 1 | 2016 | 149 | 0.440 |
Why?
| | Herpes Genitalis | 7 | 2014 | 16 | 0.440 |
Why?
| | Blood | 1 | 2014 | 107 | 0.430 |
Why?
| | Infant, Newborn | 28 | 2023 | 6079 | 0.420 |
Why?
| | Immunogenicity, Vaccine | 4 | 2022 | 30 | 0.410 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 385 | 0.410 |
Why?
| | Vaccines | 3 | 2018 | 406 | 0.400 |
Why?
| | Herpes Labialis | 3 | 2013 | 8 | 0.400 |
Why?
| | Time Factors | 20 | 2021 | 6828 | 0.400 |
Why?
| | Trigeminal Ganglion | 2 | 2003 | 25 | 0.400 |
Why?
| | Placebos | 8 | 2017 | 199 | 0.400 |
Why?
| | Aging | 10 | 2017 | 1864 | 0.380 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2023 | 9 | 0.380 |
Why?
| | Retrospective Studies | 16 | 2023 | 15657 | 0.380 |
Why?
| | Sensory Receptor Cells | 1 | 2012 | 98 | 0.370 |
Why?
| | Young Adult | 24 | 2023 | 13209 | 0.370 |
Why?
| | RNA, Viral | 21 | 2018 | 656 | 0.370 |
Why?
| | Communicable Diseases | 1 | 2014 | 159 | 0.360 |
Why?
| | United States | 17 | 2023 | 14841 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1477 | 0.350 |
Why?
| | Quality of Life | 7 | 2021 | 2892 | 0.340 |
Why?
| | Human papillomavirus 18 | 5 | 2018 | 16 | 0.330 |
Why?
| | Pregnancy | 20 | 2020 | 6763 | 0.330 |
Why?
| | Databases, Factual | 4 | 2019 | 1357 | 0.330 |
Why?
| | Human papillomavirus 16 | 5 | 2018 | 35 | 0.330 |
Why?
| | Glycoproteins | 2 | 2023 | 342 | 0.330 |
Why?
| | Animals | 42 | 2021 | 36940 | 0.320 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 248 | 0.320 |
Why?
| | Chagas Cardiomyopathy | 4 | 2007 | 24 | 0.310 |
Why?
| | Cost-Benefit Analysis | 4 | 2024 | 591 | 0.310 |
Why?
| | Poverty | 1 | 2013 | 521 | 0.310 |
Why?
| | Vaccines, Subunit | 5 | 2021 | 49 | 0.310 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.310 |
Why?
| | Risk Factors | 20 | 2023 | 10388 | 0.300 |
Why?
| | Frail Elderly | 2 | 2020 | 131 | 0.300 |
Why?
| | Treatment Outcome | 19 | 2016 | 10811 | 0.300 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2018 | 24 | 0.280 |
Why?
| | Epitopes | 4 | 2005 | 479 | 0.280 |
Why?
| | Activities of Daily Living | 3 | 2021 | 413 | 0.280 |
Why?
| | Meningitis, Viral | 3 | 1997 | 21 | 0.280 |
Why?
| | Meningitis | 1 | 2008 | 79 | 0.270 |
Why?
| | Hemagglutination Inhibition Tests | 7 | 2017 | 38 | 0.270 |
Why?
| | Seasons | 3 | 2023 | 547 | 0.270 |
Why?
| | Viral Plaque Assay | 8 | 2012 | 31 | 0.270 |
Why?
| | Viremia | 5 | 2018 | 138 | 0.270 |
Why?
| | Recurrence | 14 | 2019 | 1060 | 0.260 |
Why?
| | Autoantibodies | 3 | 2007 | 1496 | 0.260 |
Why?
| | Research Design | 2 | 2013 | 1139 | 0.260 |
Why?
| | Cells, Cultured | 19 | 2012 | 4193 | 0.260 |
Why?
| | Cytokines | 7 | 2018 | 2085 | 0.260 |
Why?
| | Prospective Studies | 25 | 2019 | 7604 | 0.260 |
Why?
| | Neurons | 6 | 2003 | 1590 | 0.250 |
Why?
| | Immunocompetence | 4 | 2019 | 42 | 0.250 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2017 | 128 | 0.250 |
Why?
| | Neoplasms | 3 | 2016 | 2671 | 0.240 |
Why?
| | Nucleic Acid Hybridization | 11 | 2006 | 190 | 0.240 |
Why?
| | Sleep Wake Disorders | 4 | 2013 | 286 | 0.240 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 250 | 0.240 |
Why?
| | Virus Replication | 12 | 2018 | 483 | 0.230 |
Why?
| | Cross Reactions | 6 | 2014 | 133 | 0.230 |
Why?
| | Nucleosides | 1 | 2004 | 27 | 0.230 |
Why?
| | Cell Count | 2 | 2005 | 324 | 0.230 |
Why?
| | Severity of Illness Index | 14 | 2015 | 2828 | 0.230 |
Why?
| | Intestines | 2 | 2018 | 357 | 0.230 |
Why?
| | Vaccine Potency | 3 | 2019 | 6 | 0.230 |
Why?
| | Viral Proteins | 5 | 2018 | 342 | 0.220 |
Why?
| | Health Resources | 2 | 2019 | 120 | 0.220 |
Why?
| | Influenza A virus | 5 | 2012 | 107 | 0.220 |
Why?
| | Molecular Sequence Data | 9 | 2006 | 2900 | 0.220 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 88 | 0.220 |
Why?
| | Depressive Disorder, Major | 4 | 2013 | 364 | 0.220 |
Why?
| | Phosphoproteins | 1 | 2006 | 338 | 0.210 |
Why?
| | Monocytes | 7 | 2005 | 563 | 0.210 |
Why?
| | Herpesvirus 4, Human | 3 | 2014 | 166 | 0.210 |
Why?
| | Interferons | 9 | 1982 | 202 | 0.210 |
Why?
| | Cholecalciferol | 1 | 2024 | 60 | 0.210 |
Why?
| | Neuralgia | 4 | 2010 | 133 | 0.210 |
Why?
| | Genetic Variation | 1 | 2008 | 991 | 0.210 |
Why?
| | Immunoassay | 2 | 2017 | 115 | 0.200 |
Why?
| | Long-Term Care | 1 | 2024 | 107 | 0.200 |
Why?
| | Antibody Affinity | 2 | 2021 | 60 | 0.200 |
Why?
| | Cricetinae | 6 | 2007 | 289 | 0.200 |
Why?
| | Enterovirus Infections | 5 | 1995 | 177 | 0.200 |
Why?
| | Ganglia, Spinal | 2 | 1993 | 77 | 0.200 |
Why?
| | Encephalitis | 2 | 1995 | 136 | 0.200 |
Why?
| | Developing Countries | 2 | 2016 | 307 | 0.190 |
Why?
| | Drug Combinations | 2 | 2022 | 343 | 0.190 |
Why?
| | CHO Cells | 3 | 2007 | 161 | 0.190 |
Why?
| | Pain Measurement | 8 | 2019 | 521 | 0.190 |
Why?
| | Lymphocyte Activation | 13 | 2015 | 1142 | 0.190 |
Why?
| | Virus Activation | 4 | 2010 | 88 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2018 | 1353 | 0.190 |
Why?
| | Papillomaviridae | 3 | 2011 | 125 | 0.190 |
Why?
| | Lymphocytosis | 1 | 2021 | 11 | 0.190 |
Why?
| | Longitudinal Studies | 8 | 2018 | 2844 | 0.180 |
Why?
| | Mice | 12 | 2021 | 17787 | 0.180 |
Why?
| | Immunosenescence | 1 | 2021 | 5 | 0.180 |
Why?
| | Cell Separation | 1 | 2002 | 318 | 0.180 |
Why?
| | Virology | 1 | 2001 | 24 | 0.180 |
Why?
| | Herpes Simplex Virus Vaccines | 2 | 2012 | 4 | 0.170 |
Why?
| | Fetal Diseases | 4 | 1991 | 173 | 0.170 |
Why?
| | Genes, Protozoan | 1 | 2000 | 13 | 0.170 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 73 | 0.170 |
Why?
| | Fibroblasts | 10 | 2018 | 996 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 6 | 2016 | 390 | 0.170 |
Why?
| | Intermediate Filament Proteins | 1 | 2000 | 57 | 0.170 |
Why?
| | Case-Control Studies | 5 | 2018 | 3556 | 0.170 |
Why?
| | RNA Helicases | 1 | 2000 | 30 | 0.170 |
Why?
| | Cell Line | 16 | 2018 | 2847 | 0.170 |
Why?
| | Amino Acid Sequence | 5 | 2006 | 2139 | 0.170 |
Why?
| | Vitamin D | 1 | 2024 | 397 | 0.170 |
Why?
| | Terminal Repeat Sequences | 1 | 2000 | 17 | 0.170 |
Why?
| | Immunoglobulin A | 3 | 2017 | 211 | 0.170 |
Why?
| | HIV-1 | 5 | 2018 | 864 | 0.170 |
Why?
| | Short Interspersed Nucleotide Elements | 1 | 2000 | 11 | 0.170 |
Why?
| | Feces | 3 | 2017 | 484 | 0.170 |
Why?
| | Health Services for the Aged | 1 | 2001 | 80 | 0.160 |
Why?
| | Enterovirus | 3 | 1995 | 86 | 0.160 |
Why?
| | Laboratories | 1 | 2001 | 113 | 0.160 |
Why?
| | Cohort Studies | 10 | 2022 | 5742 | 0.160 |
Why?
| | Antidepressive Agents | 2 | 2013 | 236 | 0.160 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1993 | 230 | 0.160 |
Why?
| | Retroelements | 1 | 2000 | 48 | 0.160 |
Why?
| | Epitope Mapping | 3 | 2005 | 62 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2001 | 771 | 0.160 |
Why?
| | Myocytes, Cardiac | 1 | 2004 | 526 | 0.160 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 219 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 5 | 2010 | 558 | 0.160 |
Why?
| | Immunization, Passive | 4 | 1994 | 90 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 561 | 0.160 |
Why?
| | Base Sequence | 10 | 2007 | 2181 | 0.160 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2022 | 261 | 0.160 |
Why?
| | Immunization Schedule | 3 | 2016 | 197 | 0.150 |
Why?
| | Hemophilia A | 2 | 1993 | 139 | 0.150 |
Why?
| | Pneumococcal Infections | 2 | 2013 | 115 | 0.150 |
Why?
| | Heart Transplantation | 2 | 2007 | 754 | 0.150 |
Why?
| | Myocardium | 3 | 2001 | 1002 | 0.150 |
Why?
| | Cholera Toxin | 1 | 2018 | 32 | 0.150 |
Why?
| | Autophagosomes | 1 | 2018 | 19 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 8 | 2005 | 361 | 0.150 |
Why?
| | Infant, Premature, Diseases | 3 | 1995 | 101 | 0.150 |
Why?
| | Age Distribution | 3 | 2016 | 392 | 0.140 |
Why?
| | Sex Distribution | 3 | 2016 | 375 | 0.140 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 70 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2006 | 871 | 0.140 |
Why?
| | Viral Fusion Proteins | 1 | 2017 | 17 | 0.140 |
Why?
| | Lymphocytes | 8 | 1998 | 397 | 0.140 |
Why?
| | Immune Evasion | 1 | 2018 | 58 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1066 | 0.140 |
Why?
| | Simian virus 40 | 11 | 1977 | 24 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1024 | 0.140 |
Why?
| | Genes, Viral | 2 | 2006 | 88 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 141 | 0.140 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 76 | 0.140 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 50 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1509 | 0.140 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 6 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 62 | 0.140 |
Why?
| | Protein Subunits | 1 | 2018 | 239 | 0.140 |
Why?
| | Cryopreservation | 1 | 2018 | 100 | 0.140 |
Why?
| | Cell Division | 5 | 2003 | 794 | 0.140 |
Why?
| | Models, Biological | 1 | 2005 | 1783 | 0.140 |
Why?
| | Cost of Illness | 5 | 2014 | 308 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 117 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2017 | 77 | 0.130 |
Why?
| | Infectious Mononucleosis | 2 | 1991 | 10 | 0.130 |
Why?
| | Depression | 3 | 2013 | 1397 | 0.130 |
Why?
| | Receptors, Muscarinic | 1 | 1996 | 19 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 413 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 45 | 0.130 |
Why?
| | Africa | 1 | 2017 | 108 | 0.130 |
Why?
| | Antibodies, Bacterial | 3 | 2013 | 146 | 0.130 |
Why?
| | Foscarnet | 3 | 2003 | 19 | 0.130 |
Why?
| | Triatoma | 2 | 2006 | 7 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Latex Fixation Tests | 1 | 1996 | 3 | 0.130 |
Why?
| | Erythema | 1 | 2016 | 29 | 0.130 |
Why?
| | Comorbidity | 3 | 2019 | 1622 | 0.130 |
Why?
| | Frailty | 1 | 2019 | 170 | 0.120 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.120 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.120 |
Why?
| | Insect Vectors | 2 | 2006 | 39 | 0.120 |
Why?
| | Peptide Fragments | 3 | 2007 | 706 | 0.120 |
Why?
| | Ribavirin | 2 | 1994 | 91 | 0.120 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 69 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 284 | 0.120 |
Why?
| | Ritonavir | 1 | 2016 | 74 | 0.120 |
Why?
| | Hospitalization | 2 | 2023 | 2199 | 0.120 |
Why?
| | Dipeptides | 1 | 2015 | 50 | 0.120 |
Why?
| | Bone Marrow Transplantation | 3 | 1990 | 286 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2015 | 622 | 0.120 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 87 | 0.120 |
Why?
| | BK Virus | 1 | 2015 | 17 | 0.120 |
Why?
| | Chronic Disease | 6 | 2019 | 1793 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 412 | 0.120 |
Why?
| | Brain Stem | 1 | 1995 | 94 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 249 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 364 | 0.120 |
Why?
| | Genotype | 3 | 2008 | 1916 | 0.120 |
Why?
| | Guatemala | 1 | 2016 | 327 | 0.120 |
Why?
| | Data Interpretation, Statistical | 3 | 2019 | 363 | 0.110 |
Why?
| | Propylene Glycols | 1 | 2015 | 28 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.110 |
Why?
| | Medication Reconciliation | 1 | 2015 | 29 | 0.110 |
Why?
| | Global Health | 1 | 2018 | 386 | 0.110 |
Why?
| | Reproducibility of Results | 5 | 2013 | 3284 | 0.110 |
Why?
| | Sphingosine | 1 | 2015 | 46 | 0.110 |
Why?
| | Transfusion Reaction | 1 | 1995 | 45 | 0.110 |
Why?
| | Survival Rate | 3 | 2016 | 1972 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | COS Cells | 2 | 2007 | 188 | 0.110 |
Why?
| | Maus Elberfeld virus | 2 | 1991 | 5 | 0.110 |
Why?
| | Respiratory Syncytial Viruses | 4 | 1993 | 54 | 0.110 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 97 | 0.110 |
Why?
| | Chlamydia trachomatis | 2 | 1991 | 49 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 3 | 1995 | 165 | 0.110 |
Why?
| | Hemagglutinins, Viral | 1 | 1994 | 7 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 203 | 0.110 |
Why?
| | Species Specificity | 3 | 2006 | 585 | 0.110 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2021 | 106 | 0.110 |
Why?
| | Laryngeal Diseases | 1 | 1994 | 31 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 1992 | 44 | 0.110 |
Why?
| | Lymphoma | 1 | 2015 | 208 | 0.110 |
Why?
| | Needs Assessment | 1 | 2016 | 376 | 0.110 |
Why?
| | Rats | 4 | 2006 | 5647 | 0.110 |
Why?
| | Autoantigens | 1 | 1996 | 430 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 5 | 1995 | 132 | 0.100 |
Why?
| | Zidovudine | 2 | 2015 | 78 | 0.100 |
Why?
| | Lamivudine | 2 | 2015 | 63 | 0.100 |
Why?
| | Analgesics | 3 | 2010 | 206 | 0.100 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 30 | 0.100 |
Why?
| | Placenta | 2 | 1991 | 750 | 0.100 |
Why?
| | Cross-Over Studies | 2 | 2013 | 564 | 0.100 |
Why?
| | Ethics, Research | 1 | 2013 | 33 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2013 | 496 | 0.100 |
Why?
| | Health Status | 2 | 2010 | 792 | 0.100 |
Why?
| | Research Subjects | 1 | 2013 | 42 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1587 | 0.100 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1272 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 181 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 289 | 0.100 |
Why?
| | Risk Assessment | 4 | 2016 | 3457 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 460 | 0.100 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 47 | 0.100 |
Why?
| | Measles Vaccine | 1 | 2012 | 21 | 0.100 |
Why?
| | Killer Cells, Natural | 1 | 1996 | 449 | 0.100 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 95 | 0.100 |
Why?
| | Indoles | 1 | 2015 | 412 | 0.090 |
Why?
| | Human papillomavirus 31 | 1 | 2011 | 1 | 0.090 |
Why?
| | Drug Resistance, Microbial | 4 | 2001 | 71 | 0.090 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.090 |
Why?
| | Colorado | 4 | 2018 | 4565 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2015 | 890 | 0.090 |
Why?
| | Meningitis, Aseptic | 1 | 1991 | 13 | 0.090 |
Why?
| | Flow Cytometry | 5 | 2017 | 1178 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2011 | 173 | 0.090 |
Why?
| | Insurance, Health | 1 | 2014 | 283 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 99 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 1991 | 42 | 0.090 |
Why?
| | Linear Models | 2 | 2010 | 849 | 0.090 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1996 | 41 | 0.090 |
Why?
| | Mutation | 5 | 2009 | 3958 | 0.090 |
Why?
| | Macrophages | 3 | 2005 | 1547 | 0.090 |
Why?
| | Neurogenesis | 1 | 2012 | 149 | 0.090 |
Why?
| | Gastroenteritis | 2 | 1989 | 69 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2012 | 156 | 0.090 |
Why?
| | Sequence Alignment | 2 | 2008 | 343 | 0.090 |
Why?
| | Drug Design | 1 | 2012 | 167 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2010 | 48 | 0.090 |
Why?
| | Epidemiological Monitoring | 3 | 2018 | 60 | 0.090 |
Why?
| | Adjuvants, Pharmaceutic | 2 | 2022 | 11 | 0.090 |
Why?
| | Exanthema | 1 | 2011 | 78 | 0.080 |
Why?
| | Serum | 1 | 2010 | 59 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1946 | 0.080 |
Why?
| | Adenoviridae | 9 | 2005 | 193 | 0.080 |
Why?
| | Electrocardiography | 2 | 2005 | 629 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 986 | 0.080 |
Why?
| | Herpesviridae | 2 | 1981 | 23 | 0.080 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2010 | 30 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Heart Rate | 2 | 2006 | 822 | 0.080 |
Why?
| | Antigen-Presenting Cells | 5 | 2010 | 156 | 0.080 |
Why?
| | Enterovirus B, Human | 2 | 1988 | 26 | 0.080 |
Why?
| | Immunoglobulin M | 1 | 1991 | 289 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 390 | 0.080 |
Why?
| | Dermatomyositis | 1 | 1989 | 27 | 0.080 |
Why?
| | DNA, Kinetoplast | 2 | 2006 | 2 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 435 | 0.080 |
Why?
| | Pilot Projects | 1 | 2015 | 1710 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 45 | 0.080 |
Why?
| | Receptors, Virus | 2 | 2006 | 83 | 0.080 |
Why?
| | Poliovirus | 2 | 2001 | 85 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 5778 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 11 | 0.080 |
Why?
| | Placenta Diseases | 1 | 1989 | 18 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 515 | 0.080 |
Why?
| | Thymidine Kinase | 4 | 2001 | 15 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 167 | 0.080 |
Why?
| | Skin Diseases, Viral | 1 | 2008 | 5 | 0.080 |
Why?
| | Oligonucleotide Probes | 1 | 1988 | 51 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2000 | 2654 | 0.080 |
Why?
| | Geriatrics | 1 | 2010 | 98 | 0.070 |
Why?
| | Vagina | 1 | 2010 | 187 | 0.070 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 1986 | 69 | 0.070 |
Why?
| | Gene Expression | 2 | 2006 | 1502 | 0.070 |
Why?
| | Muscles | 1 | 1989 | 326 | 0.070 |
Why?
| | Geriatric Assessment | 1 | 2010 | 224 | 0.070 |
Why?
| | Interferon Type I | 1 | 1989 | 140 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 90 | 0.070 |
Why?
| | Kinetics | 2 | 2010 | 1670 | 0.070 |
Why?
| | Poisson Distribution | 2 | 2005 | 75 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 322 | 0.070 |
Why?
| | In Vitro Techniques | 6 | 2003 | 1092 | 0.070 |
Why?
| | Picornaviridae | 1 | 1988 | 18 | 0.070 |
Why?
| | Lipid A | 2 | 2018 | 29 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2010 | 217 | 0.070 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1988 | 29 | 0.070 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 22 | 0.070 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 229 | 0.070 |
Why?
| | Immunosorbent Techniques | 1 | 2007 | 21 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2007 | 113 | 0.070 |
Why?
| | Spinal Cord | 2 | 2001 | 370 | 0.070 |
Why?
| | Prevalence | 4 | 2018 | 2734 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 416 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 109 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 673 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.070 |
Why?
| | Receptor, IGF Type 2 | 1 | 2006 | 6 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 1692 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 69 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.070 |
Why?
| | Veterans | 1 | 2018 | 1476 | 0.070 |
Why?
| | Trypanosomatina | 1 | 2006 | 1 | 0.070 |
Why?
| | Opportunistic Infections | 3 | 1993 | 46 | 0.070 |
Why?
| | Heparitin Sulfate | 1 | 2006 | 50 | 0.060 |
Why?
| | Research | 1 | 2010 | 451 | 0.060 |
Why?
| | Immunoglobulin Fragments | 1 | 2006 | 12 | 0.060 |
Why?
| | Animal Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Neutralization Tests | 5 | 2012 | 75 | 0.060 |
Why?
| | Public Health | 1 | 2012 | 588 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 144 | 0.060 |
Why?
| | Administration, Topical | 4 | 2013 | 151 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 786 | 0.060 |
Why?
| | Random Allocation | 6 | 1992 | 353 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 889 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 1 | 2006 | 80 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2007 | 234 | 0.060 |
Why?
| | Meningococcal Vaccines | 1 | 2006 | 55 | 0.060 |
Why?
| | Trees | 1 | 2006 | 71 | 0.060 |
Why?
| | Nasopharyngeal Diseases | 1 | 1985 | 5 | 0.060 |
Why?
| | Pneumonia, Viral | 2 | 1990 | 373 | 0.060 |
Why?
| | Hybridization, Genetic | 9 | 1974 | 78 | 0.060 |
Why?
| | Logistic Models | 2 | 2010 | 2074 | 0.060 |
Why?
| | Bone Marrow | 2 | 1984 | 286 | 0.060 |
Why?
| | Endocytosis | 1 | 2006 | 172 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2007 | 812 | 0.060 |
Why?
| | Flaviviridae Infections | 1 | 2005 | 1 | 0.060 |
Why?
| | GB virus C | 1 | 2005 | 1 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1266 | 0.060 |
Why?
| | Motor Activity | 1 | 2010 | 718 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 2031 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2129 | 0.060 |
Why?
| | Hepatitis, Viral, Human | 1 | 2005 | 25 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 560 | 0.060 |
Why?
| | Normal Distribution | 1 | 2005 | 21 | 0.060 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2016 | 42 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1991 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1996 | 180 | 0.060 |
Why?
| | Conservation of Natural Resources | 1 | 2006 | 122 | 0.060 |
Why?
| | HLA Antigens | 3 | 1987 | 240 | 0.060 |
Why?
| | Open Reading Frames | 2 | 2007 | 123 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 250 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 945 | 0.060 |
Why?
| | Autopsy | 2 | 2001 | 95 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2005 | 97 | 0.060 |
Why?
| | Blotting, Western | 3 | 2015 | 1226 | 0.060 |
Why?
| | Mammals | 1 | 2006 | 283 | 0.060 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 37 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 1988 | 395 | 0.060 |
Why?
| | Risk | 3 | 2016 | 912 | 0.050 |
Why?
| | Macaca radiata | 2 | 2001 | 16 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 363 | 0.050 |
Why?
| | Mental Health | 1 | 2010 | 726 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 181 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2057 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2003 | 68 | 0.050 |
Why?
| | Sex Factors | 2 | 2003 | 2071 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2004 | 127 | 0.050 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 39 | 0.050 |
Why?
| | Demography | 2 | 2018 | 291 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 385 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2001 | 310 | 0.050 |
Why?
| | 2-Aminopurine | 2 | 2007 | 9 | 0.050 |
Why?
| | RNA | 2 | 1988 | 921 | 0.050 |
Why?
| | Adaptive Immunity | 2 | 2017 | 165 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 500 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2009 | 2189 | 0.050 |
Why?
| | Biopsy | 2 | 2000 | 1129 | 0.050 |
Why?
| | Argentina | 3 | 2006 | 26 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2003 | 160 | 0.050 |
Why?
| | Poliomyelitis | 2 | 2001 | 37 | 0.050 |
Why?
| | Maltose-Binding Proteins | 1 | 2001 | 12 | 0.050 |
Why?
| | Forecasting | 3 | 2010 | 389 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2001 | 106 | 0.050 |
Why?
| | Cell Nucleus | 3 | 1991 | 620 | 0.050 |
Why?
| | Hepatitis C | 1 | 2004 | 271 | 0.040 |
Why?
| | Respirovirus Infections | 2 | 1991 | 13 | 0.040 |
Why?
| | Spondylarthropathies | 1 | 2021 | 6 | 0.040 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2001 | 25 | 0.040 |
Why?
| | Genome, Viral | 1 | 2002 | 144 | 0.040 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2000 | 5 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 179 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2001 | 65 | 0.040 |
Why?
| | Alanine | 1 | 2001 | 152 | 0.040 |
Why?
| | Blotting, Southern | 1 | 2000 | 73 | 0.040 |
Why?
| | Expressed Sequence Tags | 1 | 2000 | 42 | 0.040 |
Why?
| | Secondary Prevention | 2 | 2013 | 233 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2001 | 303 | 0.040 |
Why?
| | Endocardium | 1 | 2000 | 35 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2001 | 534 | 0.040 |
Why?
| | Blotting, Northern | 1 | 2000 | 201 | 0.040 |
Why?
| | Sex Characteristics | 2 | 2017 | 762 | 0.040 |
Why?
| | Phosphorylation | 2 | 2002 | 1759 | 0.040 |
Why?
| | Virion | 1 | 2001 | 93 | 0.040 |
Why?
| | DNA, Protozoan | 1 | 2000 | 32 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2000 | 225 | 0.040 |
Why?
| | Consensus Sequence | 1 | 2000 | 73 | 0.040 |
Why?
| | Psoriasis | 1 | 2021 | 102 | 0.040 |
Why?
| | DEAD-box RNA Helicases | 1 | 2000 | 76 | 0.040 |
Why?
| | Sleep | 1 | 2006 | 755 | 0.040 |
Why?
| | Canada | 2 | 2012 | 418 | 0.040 |
Why?
| | Transcription, Genetic | 5 | 2000 | 1457 | 0.040 |
Why?
| | Amniotic Fluid | 3 | 1991 | 96 | 0.040 |
Why?
| | Autoimmunity | 1 | 2005 | 908 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2000 | 523 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 385 | 0.040 |
Why?
| | Enterotoxins | 2 | 1994 | 88 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 665 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2486 | 0.040 |
Why?
| | Saponins | 1 | 2018 | 8 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 1982 | 406 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 53 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 46 | 0.040 |
Why?
| | Saliva | 2 | 2010 | 242 | 0.040 |
Why?
| | Encephalitis, Viral | 1 | 1998 | 43 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 101 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 134 | 0.030 |
Why?
| | Celiac Disease | 1 | 2021 | 294 | 0.030 |
Why?
| | Immunologic Techniques | 2 | 1994 | 40 | 0.030 |
Why?
| | Glucosides | 1 | 2017 | 44 | 0.030 |
Why?
| | Sterols | 1 | 2017 | 18 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 22 | 0.030 |
Why?
| | Botswana | 1 | 2017 | 9 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 5 | 1977 | 327 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 198 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 514 | 0.030 |
Why?
| | Internationality | 1 | 2018 | 155 | 0.030 |
Why?
| | Zimbabwe | 1 | 2017 | 58 | 0.030 |
Why?
| | Chemotaxis | 1 | 2017 | 131 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 57 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 58 | 0.030 |
Why?
| | Bisoprolol | 1 | 1996 | 4 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2017 | 127 | 0.030 |
Why?
| | Plasma | 1 | 2018 | 212 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 653 | 0.030 |
Why?
| | Graft Rejection | 1 | 2000 | 624 | 0.030 |
Why?
| | Cerebrospinal Fluid | 2 | 1993 | 92 | 0.030 |
Why?
| | Acute Disease | 2 | 2011 | 1007 | 0.030 |
Why?
| | Sinusitis | 1 | 1999 | 221 | 0.030 |
Why?
| | Immune Tolerance | 4 | 1998 | 363 | 0.030 |
Why?
| | Leukemia, Lymphoid | 2 | 1986 | 27 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 4149 | 0.030 |
Why?
| | Propanolamines | 1 | 1996 | 96 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 53 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 82 | 0.030 |
Why?
| | False Positive Reactions | 1 | 1996 | 115 | 0.030 |
Why?
| | Amniocentesis | 2 | 1991 | 25 | 0.030 |
Why?
| | Cross-Sectional Studies | 4 | 2011 | 5472 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2015 | 49 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 51 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Half-Life | 2 | 1992 | 164 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1316 | 0.030 |
Why?
| | Depressive Disorder | 1 | 1998 | 379 | 0.030 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 530 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 314 | 0.030 |
Why?
| | Vomiting | 1 | 2015 | 130 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 305 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2007 | 79 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2015 | 40 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 63 | 0.030 |
Why?
| | Breast Feeding | 1 | 2018 | 440 | 0.030 |
Why?
| | Headache | 1 | 2015 | 147 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 146 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 347 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 323 | 0.030 |
Why?
| | Belgium | 1 | 2014 | 13 | 0.030 |
Why?
| | Bacterial Proteins | 1 | 2000 | 879 | 0.030 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2014 | 3 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 108 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 48 | 0.030 |
Why?
| | Rubella | 1 | 1974 | 24 | 0.030 |
Why?
| | Culture Media | 2 | 1984 | 165 | 0.030 |
Why?
| | Tetanus Toxoid | 1 | 1994 | 35 | 0.030 |
Why?
| | Probability | 2 | 2005 | 304 | 0.030 |
Why?
| | Immunoblotting | 1 | 1994 | 308 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 25 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 33 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 170 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 165 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 431 | 0.030 |
Why?
| | Phenotype | 1 | 2002 | 3196 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 200 | 0.030 |
Why?
| | Developed Countries | 1 | 2013 | 39 | 0.020 |
Why?
| | Mortality | 1 | 2015 | 362 | 0.020 |
Why?
| | Haplorhini | 8 | 1974 | 52 | 0.020 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 3 | 0.020 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 105 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 904 | 0.020 |
Why?
| | Skin | 2 | 1989 | 752 | 0.020 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 16 | 0.020 |
Why?
| | Safety | 1 | 1994 | 338 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1167 | 0.020 |
Why?
| | Genetics, Microbial | 3 | 1971 | 10 | 0.020 |
Why?
| | Genitalia, Female | 1 | 2012 | 38 | 0.020 |
Why?
| | gamma-Globulins | 1 | 1991 | 18 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 1991 | 10 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 1991 | 14 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 678 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 683 | 0.020 |
Why?
| | Absenteeism | 1 | 2012 | 49 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 27 | 0.020 |
Why?
| | Hospitals, University | 1 | 1991 | 182 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 447 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 39 | 0.020 |
Why?
| | Inflammation | 2 | 2017 | 2837 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2010 | 2 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 13 | 0.020 |
Why?
| | North America | 1 | 2012 | 313 | 0.020 |
Why?
| | Tritium | 7 | 1974 | 76 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 565 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1483 | 0.020 |
Why?
| | Europe | 1 | 2012 | 414 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 75 | 0.020 |
Why?
| | Schwann Cells | 1 | 1990 | 34 | 0.020 |
Why?
| | Antigens | 2 | 1970 | 357 | 0.020 |
Why?
| | Bacterial Infections | 2 | 2001 | 250 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 58 | 0.020 |
Why?
| | DNA | 4 | 1988 | 1459 | 0.020 |
Why?
| | Antigens, Surface | 2 | 1987 | 154 | 0.020 |
Why?
| | Serotyping | 2 | 1988 | 32 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2475 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 801 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 123 | 0.020 |
Why?
| | Gestational Age | 2 | 1989 | 910 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1774 | 0.020 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 11 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Contraceptive Devices, Male | 1 | 1989 | 1 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2001 | 316 | 0.020 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 1989 | 5 | 0.020 |
Why?
| | Spermatocidal Agents | 1 | 1989 | 7 | 0.020 |
Why?
| | Ribonucleosides | 1 | 1989 | 6 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 605 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 816 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 241 | 0.020 |
Why?
| | Thymidine | 4 | 1980 | 60 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1988 | 17 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1738 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2009 | 107 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 186 | 0.020 |
Why?
| | Virus Cultivation | 4 | 1984 | 29 | 0.020 |
Why?
| | Astrocytes | 1 | 1990 | 210 | 0.020 |
Why?
| | Reoviridae | 1 | 1988 | 37 | 0.020 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 1988 | 37 | 0.020 |
Why?
| | Measles | 1 | 1989 | 46 | 0.020 |
Why?
| | Hepatitis | 1 | 1988 | 48 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2757 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1988 | 47 | 0.020 |
Why?
| | Reoviridae Infections | 1 | 1988 | 54 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 273 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2009 | 172 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1969 | 176 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 155 | 0.020 |
Why?
| | Fetus | 1 | 1992 | 806 | 0.020 |
Why?
| | Cytopathogenic Effect, Viral | 2 | 1982 | 14 | 0.020 |
Why?
| | Microscopy, Electron | 3 | 2001 | 443 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 66 | 0.020 |
Why?
| | Noma | 1 | 1986 | 2 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 13 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 280 | 0.020 |
Why?
| | Xenodiagnosis | 1 | 2006 | 2 | 0.020 |
Why?
| | Biliary Atresia | 1 | 1988 | 163 | 0.020 |
Why?
| | Australia | 1 | 2008 | 315 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1988 | 132 | 0.020 |
Why?
| | Valine | 1 | 2007 | 82 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2553 | 0.020 |
Why?
| | Embryo, Mammalian | 3 | 1973 | 232 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1999 | 1809 | 0.020 |
Why?
| | Interleukin-4 | 2 | 1998 | 216 | 0.020 |
Why?
| | Kidney | 9 | 1975 | 1468 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2007 | 307 | 0.020 |
Why?
| | Ketones | 1 | 1986 | 49 | 0.020 |
Why?
| | RNA, Ribosomal | 1 | 2006 | 168 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1985 | 42 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.010 |
Why?
| | Gene Amplification | 1 | 2006 | 104 | 0.010 |
Why?
| | Nectins | 1 | 2005 | 6 | 0.010 |
Why?
| | Mass Screening | 1 | 2014 | 1287 | 0.010 |
Why?
| | Residence Characteristics | 1 | 2008 | 351 | 0.010 |
Why?
| | Lymphoproliferative Disorders | 1 | 1985 | 57 | 0.010 |
Why?
| | Factor Analysis, Statistical | 1 | 2006 | 283 | 0.010 |
Why?
| | California | 1 | 2006 | 431 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2005 | 115 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 2006 | 169 | 0.010 |
Why?
| | Carbon Isotopes | 5 | 1973 | 144 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1984 | 44 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 224 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2005 | 185 | 0.010 |
Why?
| | Hexuronic Acids | 1 | 1984 | 23 | 0.010 |
Why?
| | Glucuronic Acid | 1 | 1984 | 25 | 0.010 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1988 | 257 | 0.010 |
Why?
| | Alginates | 1 | 1984 | 46 | 0.010 |
Why?
| | Freezing | 1 | 1984 | 90 | 0.010 |
Why?
| | Filtration | 1 | 1984 | 72 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 641 | 0.010 |
Why?
| | Culture Techniques | 4 | 1973 | 81 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1984 | 316 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 622 | 0.010 |
Why?
| | Fetal Blood | 1 | 1985 | 327 | 0.010 |
Why?
| | Stomatitis, Herpetic | 1 | 1982 | 5 | 0.010 |
Why?
| | Phosphonoacetic Acid | 1 | 1982 | 10 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1289 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 843 | 0.010 |
Why?
| | Rural Population | 1 | 2006 | 563 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1982 | 34 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4030 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2001 | 34 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 691 | 0.010 |
Why?
| | Ulnar Nerve | 1 | 2001 | 15 | 0.010 |
Why?
| | Brain | 1 | 1993 | 2668 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 778 | 0.010 |
Why?
| | Administration, Oral | 2 | 1997 | 816 | 0.010 |
Why?
| | Temperature | 1 | 1984 | 679 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 345 | 0.010 |
Why?
| | Cell Survival | 1 | 1984 | 1120 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 4295 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1980 | 30 | 0.010 |
Why?
| | Serum Albumin | 1 | 2001 | 150 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2004 | 546 | 0.010 |
Why?
| | Neuroglia | 1 | 2001 | 173 | 0.010 |
Why?
| | Cell Communication | 1 | 1982 | 315 | 0.010 |
Why?
| | Ribosomes | 1 | 2001 | 186 | 0.010 |
Why?
| | Phagocytosis | 1 | 1982 | 380 | 0.010 |
Why?
| | Leukocytes | 1 | 1981 | 311 | 0.010 |
Why?
| | Air Microbiology | 1 | 1980 | 47 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 8 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1979 | 19 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 40 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1979 | 171 | 0.010 |
Why?
| | Mitogens | 1 | 1978 | 61 | 0.010 |
Why?
| | Lectins | 1 | 1978 | 49 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 167 | 0.010 |
Why?
| | Rabbits | 1 | 1979 | 794 | 0.010 |
Why?
| | Th2 Cells | 1 | 1998 | 176 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 1993 | 383 | 0.010 |
Why?
| | Amanitins | 1 | 1977 | 4 | 0.010 |
Why?
| | Cross Infection | 1 | 1980 | 256 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 3 | 1971 | 41 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1997 | 90 | 0.010 |
Why?
| | Interleukin-10 | 1 | 1998 | 302 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 700 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1999 | 1236 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 1975 | 17 | 0.010 |
Why?
| | Indicator Dilution Techniques | 1 | 1994 | 11 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 696 | 0.010 |
Why?
| | Uridine | 2 | 1973 | 30 | 0.010 |
Why?
| | Heart Defects, Congenital | 2 | 1993 | 842 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 1999 | 740 | 0.010 |
Why?
| | Centrifugation, Zonal | 2 | 1971 | 2 | 0.010 |
Why?
| | Abortion, Therapeutic | 1 | 1974 | 3 | 0.010 |
Why?
| | Rubella virus | 1 | 1974 | 7 | 0.010 |
Why?
| | Cesium | 2 | 1971 | 20 | 0.010 |
Why?
| | Molecular Biology | 2 | 1971 | 59 | 0.010 |
Why?
| | Sucrose | 2 | 1971 | 110 | 0.010 |
Why?
| | Chlorides | 2 | 1971 | 136 | 0.010 |
Why?
| | Complement Fixation Tests | 2 | 1984 | 6 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 1975 | 402 | 0.010 |
Why?
| | Hemagglutination Tests | 1 | 1991 | 7 | 0.010 |
Why?
| | Genes | 1 | 1971 | 230 | 0.010 |
Why?
| | Stress, Psychological | 1 | 1998 | 1100 | 0.010 |
Why?
| | Population Surveillance | 1 | 1993 | 482 | 0.010 |
Why?
| | Nonoxynol | 1 | 1989 | 4 | 0.000 |
Why?
| | Latex | 1 | 1989 | 9 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1975 | 708 | 0.000 |
Why?
| | Suspensions | 1 | 1987 | 36 | 0.000 |
Why?
| | Ribonucleases | 1 | 1987 | 55 | 0.000 |
Why?
| | Chloroquine | 1 | 1987 | 54 | 0.000 |
Why?
| | Deltaretrovirus | 1 | 1986 | 12 | 0.000 |
Why?
| | Binding, Competitive | 1 | 1985 | 202 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 329 | 0.000 |
Why?
| | Mitosis | 1 | 1985 | 192 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1985 | 367 | 0.000 |
Why?
| | Serologic Tests | 1 | 1983 | 54 | 0.000 |
Why?
| | Histocompatibility Antigens | 2 | 1974 | 105 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1982 | 40 | 0.000 |
Why?
| | Leukemia | 1 | 1983 | 240 | 0.000 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1980 | 4 | 0.000 |
Why?
| | Air Movements | 1 | 1980 | 10 | 0.000 |
Why?
| | Hospital Units | 1 | 1980 | 29 | 0.000 |
Why?
| | Boston | 1 | 1980 | 91 | 0.000 |
Why?
| | Liver | 1 | 1988 | 1943 | 0.000 |
Why?
| | Communicable Disease Control | 1 | 1980 | 82 | 0.000 |
Why?
| | Methods | 1 | 1978 | 65 | 0.000 |
Why?
| | p-Fluorophenylalanine | 1 | 1976 | 2 | 0.000 |
Why?
| | Cycloheximide | 1 | 1976 | 55 | 0.000 |
Why?
| | Hospitals, Pediatric | 1 | 1980 | 508 | 0.000 |
Why?
| | Inclusion Bodies, Viral | 1 | 1975 | 3 | 0.000 |
Why?
| | Cytoplasm | 1 | 1976 | 274 | 0.000 |
Why?
| | Cadaver | 1 | 1975 | 296 | 0.000 |
Why?
| | Transplantation, Homologous | 1 | 1975 | 416 | 0.000 |
Why?
| | Genetic Code | 1 | 1971 | 22 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1971 | 32 | 0.000 |
Why?
| | Chymotrypsin | 1 | 1971 | 22 | 0.000 |
Why?
| | Platinum | 1 | 1971 | 50 | 0.000 |
Why?
| | Molecular Weight | 1 | 1971 | 335 | 0.000 |
Why?
| | DNA Replication | 1 | 1971 | 238 | 0.000 |
Why?
| | Carbon | 1 | 1971 | 216 | 0.000 |
Why?
| | Hot Temperature | 1 | 1971 | 391 | 0.000 |
Why?
| | Lung | 1 | 1975 | 4060 | 0.000 |
Why?
|
|
Levin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|